Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamiflu for persistent immune thrombocytopenia
MOH_2018-04-15_002030Phase 2Recruiting
- Sponsor
- ד"ר יוסף קליש
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oseltamivir in immune thrombocytopenia (ITP), sponsored by ד"ר יוסף קליש. Primary endpoints: Platelet response, Reduction in bleeding signs and 1 more. Started Jan 2018; status: recruiting.
02
Drugs
oseltamivir
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2018-04-15_002030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-15_002030.